SCHEMBL30108214

SCHEMBL30108214

CN1CCN(c2cccc(-c3ccccc3)c2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.64
▸ HTR7 P34969 1/20 0.64
▸ ADRA2C P18825 1/20 0.62
▸ HTR3A P46098 1/20 0.56
▸ AGXT P21549 1/20 0.55
▸ USP2 O75604 4/20 0.54
▸ HSD17B10 Q99714 4/20 0.54
▸ MAPK1 P28482 3/20 0.54
▸ CYP1A2 P05177 3/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ DHFR P00374 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15538190 0.90 HTR7 (0.75) HTR1AHTR7USP2HSD17B10MAPK1
SCHEMBL24061149 0.88 ADRA2C (0.57) HTR1AHTR7ADRA2CHTR3AAGXT
SCHEMBL26378183 0.84 ADRA2C (0.53) HTR1AHTR7ADRA2CHTR3AAGXT
SCHEMBL30108226 0.82 MELK (0.60) ADRA2CHTR3AALDH1A1SMN1; SMN2
SCHEMBL27497441 0.82 HTR1A (0.70) HTR1AHTR7AGXTUSP2HSD17B10
SCHEMBL7610501 0.82 HTR7 (0.60) HTR1AHTR7USP2HSD17B10MAPK1
SCHEMBL149502 0.82 KMT2A (0.61) HTR1AADRA2CHTR3AHSD17B10MAPK1
SCHEMBL23220824 0.82 KMT2A (0.61) HTR1AADRA2CHTR3AHSD17B10MAPK1
SCHEMBL23220843 0.82 KMT2A (0.61) HTR1AADRA2CHTR3AHSD17B10MAPK1
SCHEMBL7498216 0.81 ADRB1 (0.61) HTR1AHTR7USP2HSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 — — US claimed
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG A SOCIO HOLDINGS CO LTD (KR) 2023-01-05 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs MERTK, ERBB2, SRC HTR1A 2823/4885HTR7 1904/4885ADRA2C 496/4885
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS MERTK, ERBB2, SRC HTR1A 2823/4885HTR7 1904/4885ADRA2C 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback